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ABSTRACT
Despite more than a century of evolving federal 
legislation, there remain many unapproved 
drugs on the United States (US) market. This 
article reviews the history of drug approval in the 
US, beginning with the landmark Pure Food and 
Drug Act of 1906, through to the development 
of the US Food and Drug Administration (FDA). 
The Pure Food and Drug Act of 1906 was the 
first comprehensive federal legislation covering 
drug regulation. Intervening legislation, such 
as the Federal Food, Drug, and Cosmetic Act of 
1938 and Kefauver-Harris Amendments in 1962, 
was later instituted. In June 2006, a century after 
the development of the FDA as an enforcement 
body, an initiative was undertaken to remove 
unapproved drugs from the marketplace. The 
Marketed Unapproved Drugs - Compliance 
Policy Guide outlines enforcement policies 
aimed at efficiently and rationally bringing all 
unapproved and illegally marketed drugs into 
the approval process, or discontinuing their 
manufacture, distribution, and sale. The FDA has 
been actively pursuing control of unapproved 
drugs in recent years, with an approach 
concentrating on drug safety to ensure optimal 
public health and consumer protection.
Keywords: drug approval; FDA; unapproved 
drugs
INTRODUCTION
The United States (US) Food and Drug 
Administration (FDA) has grown over the 
past century, from a single, unidentified 
chemist in 1862 in the US Department of 
Agriculture to the present-day organization 
dedicated to promoting and protecting 
public health through the regulation of drugs 
and other products within its purview 
(Figure 1). The Pure Food and Drug Act of 
1906 was the first comprehensive federal 
legislation covering drug regulation. This 
article reviews the history of drug approval 
in the US, from the landmark 1906 Act 
through significant intervening legislation 
and development of the FDA, culminating 
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a century later when, in June 2006, the 
FDA announced an initiative to remove 
unapproved drugs from the marketplace, 
many of which remain illegally marketed. 
Final guidance for this initiative, the 
Marketed Unapproved Drugs - Compliance 
Policy Guide,1 outlines enforcement policies 
designed to efficiently shepherd all such 
drugs through the approval process. In recent 
years, the FDA has stepped up its oversight 
*Also known as the Wiley act; changed the government’s handling of the adulteration and misbranding of food and drugs, 
and supported national food and drug regulation through public advocacy.
†Provisions included the ability of the FDA to require evidence of safety for new drugs, determine standards for food, and 
inspect factories.
‡Created the line between prescription and nonprescription drugs in that dangerous drugs could not be dispensed without 
a prescription and mandated that prescription drugs bear the following legend: “Caution: Federal law prohibits dispensing 
without prescription.”
§Established the FDA’s control over clinical drug trials and mandated “good manufacturing practices.”
||OTC drugs marketed in accordance with a final monograph do not require approval of a marketing application by FDA.
¶Also known as DESI-2. Drugs are considered to be marketed illegally unless “grandfathered” or not otherwise a new drug.
#FDA’s CDER; superseded previous policies of marketing new drugs without approved NDAs or ANDAs.
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Figure 1. Timeline of the development of the FDA and subsequent regulatory actions.1 ANDA=Abreviated New Drug 
Application; CDER=Center for Drug Evaluation and Research; DESI=Drug Efficacy Study Implementation; FDA=Food 
and Drug Administration; GRAS/E=Generally Recognized as Safe and Effective; NDA=New Drug Application; 
OTC=Over-the-counter.
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and continues to actively pursue control of 
unapproved drugs, examples of which are 
also presented in this review. 
Methods
A thorough search of the published literature, 
including that available on MEDLINE/PubMed, 
was used to identify the materials referenced in 
this manuscript. Specific search terms, including, 
but not limited to, FDA, history, development, 
compliance, nitroglycerin, thalidomide, 
colchicine, and DESI, were used to perform the 
comprehensive search. In addition, archived 
files from the FDA were also accessed.
HISTORY OF DRUG APPROVAL IN 
THE US
The Pure Food and Drug Act of 1906
Few federal laws to regulate the sale and 
contents of food and pharmaceuticals in the US 
existed prior to the creation of the Pure Food 
and Drug Act, which was signed into law in 
1906 by President Theodore Roosevelt. This 
act is also known as the Wiley Act, in honor of 
its main advocate, Harvey Wiley, who is often 
referred to as the “Father of the FDA.” Wiley 
was offered the position of Chief Chemist in the 
US Department of Agriculture in 1882. On 
assuming this role in 1883, he immediately 
changed the government’s handling of the 
adulteration and misbranding of food and 
drugs, and supported national food and drug 
regulation by spurring public indignation over 
the issue. Motivated by his work with Alice 
Lakey, one million American women wrote to 
the White House in support of the Pure Food 
and Drug Act.2
Historically, under Wiley’s guidance, the 
Bureau of Chemistry began analyzing the 
influence of preservatives on human nutrition 
in 1902, which extended to the analyses of 
proprietary medicines and plant drugs in the 
following year.3 These actions occurred at a 
time when the US marketplace was awash with 
adulterated food, drug, and biologic products. 
Drug makers were able to produce and sell 
products that, in today’s marketplace, would be 
considered adulterated. For example, “Peter’s 
Specific, The Great Blood Purifier System 
Regulator” was recommended as a treatment 
for dermatologic diseases and as an alternative 
tonic, invigorator, and blood purifier.3
The label stated little, if any, of the ingredients, 
yet it was available and sold legally in the 
US. Another example was morphine-laced 
“Mrs. Winslow’s Soothing Syrup” used for 
teething and colicky babies.3
While Wiley realized the need for 
enforcement and change of this unregulated 
marketplace, it is widely believed that the 1906 
“muckraking” novel The Jungle, by the Pulitzer 
Prize-winning American author Upton Sinclair, 
was the final driving force, resulting in a meat 
inspection law and a comprehensive food and 
drug law.4 Sinclair’s novel exposed conditions 
in the US meat-packing industry and caused a 
public uproar, which contributed, in part, to the 
implementation of the Meat Inspection Act, as 
well as the Pure Food and Drug Act a few months 
after publication of the book.5
More than 200 laws would eventually follow 
the Pure Food and Drug Act of 1906, leading to 
one of the most comprehensive and effective 
public health and consumer protection networks 
in the world. The Bureau of Chemistry enforced 
the Act until 1927, when it was reorganized 
to establish the Food, Drug, and Insecticides 
Administration, which was renamed the FDA in 
1931.5 The regulatory emphasis of the bureau 
during Wiley’s tenure was foods, because he 
believed they presented more of a threat to 
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public health than adulterated or misbranded 
drugs. After Wiley’s resignation in 1912, more 
attention was focused on drug regulation, 
including the so-called “patent medicines.”5
The Federal Food, Drug, and Cosmetic Act 
of 1938
The next milestone in the evolution of the 
FDA was the Food, Drug, and Cosmetic (FD&C) 
Act of 1938, which was passed after a series of 
disreputable incidents involving drug marketing 
claims which resulted in highly publicized 
deaths. One major incident involved the legally 
marketed Elixir Sulfanilamide, which killed 
at least 105 people, including many children, 
in the spring of 1937.6 Elixir Sulfanilamide, 
the first antimicrobial sulfa drug used to treat 
streptococcal throat and other infections, was 
available in liquid form through the dissolution 
of diethylene glycol, a known deadly poison 
normally used as an antifreeze.6 Under the then-
existing drug regulations, premarketing toxicity 
testing was not required. The resulting public 
outcry from this product not only propelled 
the bill through Congress, but also helped to 
reshape the drug provisions of the new law to 
prevent the reoccurrence of such an event.6
The FD&C Act completely overhauled the 
drug regulatory system. Provisions included 
the ability of the FDA to require evidence of 
safety for new drugs, determine standards for 
food, and inspect factories.5 Previously, there 
had been no federal regulatory control ensuring 
the safety of new drugs. New drugs would 
require approval for safety through a New Drug 
Application (NDA). Those organizations that 
complete the process of submitting an NDA, and 
receive regulatory approval, obtain marketing 
exclusivity as a result, which may delay the entry 
of other approved competitor products into 
the market.5 However, holders of NDAs are not 
permitted to “manipulate statutory protections 
to inappropriately delay competition.” Those 
who attempt to do so are then reported to the 
Federal Trade Commission (FTC). An NDA was 
not required under a “grandfather clause” for 
drugs marketed prior to 1938 that had been 
previously labeled as “Generally Recognized 
as Safe and Effective (GRAS/E).” They were 
required, however, to contain the same chemical 
composition, indications, and conditions for use 
as the “grandfathered drug.”5
The FD&C Act of 1938 also mandated the 
listing of active ingredients on the drug label, 
and required labeling with adequate directions 
for use and warnings. By 1940, the FDA had 
developed more than two-dozen standardized 
warning statements for different drugs and 
determined that some drugs were too dangerous 
to be sold directly to consumers, even with 
labeled directions. In the 1948 US versus 
Sullivan case, the Supreme Court ruled that FDA 
jurisdiction extended to retail stores, thereby 
allowing the FDA to stop the illegal sales of 
drugs (eg, barbiturates and amphetamines) 
by pharmacies, defending the ability of the 
agency to define prescription-only drugs.1
The Durham-Humphrey Amendment of 1951 
clarified the vague line between prescription and 
nonprescription drugs. Under the law, dangerous 
drugs, as defined by several parameters, could 
not be dispensed without a prescription. It 
also mandated that prescription drugs bear 
the following legend: “Caution: Federal law 
prohibits dispensing without prescription.”5
Kefauver-Harris Amendments in 1962
The Kefauver-Harris Amendments to the FD&C 
Act (the 1962 Amendments) were considered the 
next major step, allowing the FDA stricter control 
over clinical drug trials. The Amendments also 
mandated “good manufacturing practices” for 
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the drug industry, established a new level of 
responsibility for the FDA, and changed the way 
Americans viewed drug-product regulation and 
the FDA. For the first time, drug manufacturers 
were required to provide evidence of efficacy 
in addition to safety before marketing. In 
addition, the Amendments required disclosure 
of accurate side effect and efficacy information 
in advertising campaigns. As a result, previously 
marketed and inexpensive generic drugs could 
no longer be repurposed and marketed under 
more expensive, new trade names, labeled as new 
“breakthrough” medications.1 This major change 
in the regulatory powers of the FDA occurred in 
response to a series of incidents which made it 
clear that more public protection was needed, 
most notably of which were the well-publicized 
issues with thalidomide.7,8 Despite its approval, 
based on safety data, the safety review did not 
include the risk of teratogenicity. As a result, 
an estimated 10,000 victims were exposed to 
thalidomide globally and developed congenital 
abnormalities from this potent teratogen.7,8
The impact of thalidomide in the US was 
minimized when the NDA marketing application 
was denied by Dr Frances Kelsey and the FDA 
until further safety studies were conducted.9 Even 
though approval was never granted for marketing 
thalidomide in the US, more than two million 
tablets were distributed for investigational use as 
a result of a flaw in the law and regulations. The 
FDA moved quickly to recover this supply from 
physicians, pharmacists, and patients.5 However, 
a few cases of thalidomide-induced abnormalities 
nonetheless occurred in the US.10,11
As previously discussed, the Kefauver-Harris 
Amendments of 1962 required that all drugs 
introduced since the FD&C Act of 1938 have 
demonstrated efficacy.1 However, a drug could 
be exempt from this requirement for several 
different reasons, including if there was no 
change in composition and labeling after 1962; 
it was used or sold on a commercial basis in the 
US before the 1962 Amendments became law; it 
was not a new drug as determined by the Act at 
that time; and it was not covered by an effective 
application. In other words, as long as a product 
was introduced to the market and contained the 
same representations regarding conditions of 
use as it did before the FD&C Act of 1938, it was 
neither considered to be a new drug nor required 
to have an approved application. Again, drugs 
that were marketed before the passage of the 
1938 Act were referred to as grandfathered drugs, 
that is, exempt as considered GRAS/E. A drug is 
not considered by the FDA to be grandfathered 
if, since 1938, there has been any change to 
formulation, dosage form, potency, route of 
administration, indication/labeling, or intended 
patient population.1
It is the responsibility of the manufacturer, or 
the distributor, of a grandfathered drug product 
to maintain files that contain the data and 
information necessary to fully document and 
support grandfathered status. The FDA believes 
that few, if any, genuinely grandfathered 
drugs remain on the market today.12 If a drug 
obtained approval between 1938 and 1962, 
the FDA generally permitted marketing of 
Identical, Related, or Similar (IRS) drugs to the 
approved drug without independent approval. 
A number of manufacturers introduced drugs 
to the marketplace between 1938 and 1962 on 
the basis of their own determination that the 
products were GRAS/E, and therefore exempt 
from the statutory new drug definition.12
In an effort to identify manufacturers who 
continued to market grandfathered drugs 
and bring them into compliance with federal 
regulations, the Kefauver-Harris Amendments 
mandated a retrospective efficacy evaluation 
of drugs approved between 1938 and 1962.1
In 1962, the FDA engaged the National 
Academy of Science/National Research Council 
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(NAS/NRC) to review the efficacy of 
approximately 3,400 drugs that were previously 
approved, based on safety data.5 The review 
by the NAS/NRC was referred to as the Drug 
Efficacy Study (DES), with the results published 
in the Federal Register. From the findings, 
the FDA provided the Drug Efficacy Study 
Implementation (DESI) review.5 Therefore, drugs 
sold in the US between 1938 and 1962 that were 
approved for safety, but not efficacy, are now 
referred to as DESI drugs. Drugs that are IRS to 
DESI drugs are also called DESI drugs.1
The DESI program required approved NDAs 
for all marketed, unapproved prescription 
drugs, or Abbreviated New Drug Applications 
(ANDA) for IRS products. These drugs are 
deemed to be marketed illegally unless it can 
be proven by the manufacturer that the drug is 
truly not a new product requiring an approved 
application.5 These applications are termed 
“abbreviated” because they do not require 
preclinical and clinical trial data to establish 
safety and effectiveness, but must demonstrate 
bioequivalency to the branded product. ANDA 
are submitted to the FDA’s Center for Drug 
Evaluation and Research, Office of Generic 
Drugs, for approval to manufacture and market 
these generic drugs as a safe, effective, low-
cost alternative to branded products. These 
generic drugs, deemed to be comparable to 
branded products in dosage form, strength, 
route of administration, quality, performance 
characteristics, and intended use, are listed in the 
FDA’s Approved Drug Products with Therapeutic 
Equivalence Evaluations (Orange Book).5
The efficacy review process was expedited 
in 1966 when the FDA contracted with the 
NAS/NRC to evaluate DESI drugs.1 By the end 
of 1981, the agency had taken regulatory action 
on 90% of all DESI products,5 despite being 
challenged in 1970, whereby the Court of 
Appeals upheld enforcement of the 1962 drug 
effectiveness amendments in the Upjohn versus 
Fitch case by ruling that commercial success 
alone does not constitute substantial evidence 
of drug safety and efficacy.1 
In 2007, there were fewer than 20 DESI 
proceedings pending review.12 In the event that 
the final DESI review determination classifies a 
drug as ineffective, the product and all its IRS 
products may not be marketed and are subject 
to enforcement action. Even if DESI and IRS 
products are found to be effective, the FDA still 
requires approval of applications as a condition 
of their continued marketing. Under these 
guidelines, DESI drugs still require an approved 
application; however, a drug with a DESI-
pending status does not require FDA approval 
and may be marketed until a final decision 
has been made and published in the Federal 
Register.12 Examples of outcomes for DESI drugs 
are shown in Table 1.
In summary, the 1962 Amendments 
eliminated drugs from the US market that were 
not proven to be effective, provided a means 
to require amendment of existing labeling to 
remain in compliance, gave new definition to 
the term “adequate and well-controlled studies,” 
and provided an improved mechanism for the 
FDA to evaluate clinical trials.1
However, many drugs came onto the market 
before 1962 without approval from the FDA. 
Many of these products claimed to be marketed 
prior to the 1938 Act or to be IRS to such a 
drug, claiming grandfathered status.1 Drugs that 
did not have Amendments approvals before 
1962, or were not IRS to drugs with approvals 
before 1962, were not subject to DESI. The FDA 
allowed these drugs to stay on the market, in 
addition to allowing new, unapproved drugs 
that were IRS to these drugs from before 1962 
to enter the market without approval for some 
time. There are an estimated five IRS products 
for every NDA product.1
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of unapproved products on the market. This 
report led to an assessment of pre-1962 non-
DESI marketed drug products by the FDA. 
The program for these marketed, unapproved 
drugs, instituted in 1984, became known as 
the Prescription Drug Wrap-up, often referred 
Table 1. Drugs evaluated under Drug Efficacy Study Implementation (DESI).
Products found ineffective under DESI Manufacturer Corporate headquarters
Arlidin® (nylidrin HCl) USV (Corvette) Bombay, India
Combid® (isopropamide iodide, prochloroperazine 
maleate)
GlaxoSmithKline Raleigh-Durham, NC,  
United States
Equagesic® (meprobamate, ethoheprazine citrate, 
acetylsalicate acid)
Wyeth Laboratories Malvern, PA, United States
Marax® (hydroxyzine HCl, ephedrine sulfate, 
theophylline)
Pfizer US Pharmaceuticals Group New York, NY, United States
Neo-medrol® (methylprednisolone acetate, 
neomycin sulfate)
Pharmacia and Upjohn Co. Bridgewater, NJ, United States
Rautrax® (raudixin, flumethiazide, potassium 
chloride)
Bristol-Myers Squibb Princeton, NJ, United States
Tuss-Ornade® (caramiphen, phenylpropanolamine) GlaxoSmithKline Raleigh-Durham, NC,  
United States
Products found effective under DESI Manufacturer Corporate headquarters
Thorazine® (chlorpromazine) GlaxoSmithKline Raleigh-Durham, NC,  
United States
Coumadin® (warfarin) Bristol-Myers Squibb Princeton, NJ, United States
Darvon® (propoxyphene) Xanodyne Pharmaceuticals, Inc. Newport, KY, United States
Diuril® (chlorothiazide) Lundbeck Inc. Deerfield, IL, United States
Elavil® (amitriptyline) Merck & Co., Inc. North Wales, PA, United States
Librium® (chlordiazepoxide) Valeant Pharmaceuticals 
International
Ontario, Canada
Nisentil® (alphaprodine) Hoffman-LaRoche, Inc. Basal, Switzerland
Methotrexate Various N/A
Heparin sodium Various N/A
Hydrocortisone acetate Various N/A
Isoniazid Various N/A
Isosorbide dinitrate Various N/A
In 1983, an unapproved, high-potency 
intravenous vitamin E (E-Ferol) caused adverse 
reactions in approximately 100 infants, 40 of 
whom died.13 This led to a 1984 Congressional 
Oversight Committee, which issued a report to 
the FDA expressing concern over the thousands 
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to as DESI-2.13 The FDA claims that most of the 
approximately 5,000 unapproved, marketed 
drugs identified were pre-1938 and unapproved, 
pre-1962 drugs, or products that are IRS to such 
a drug. They also acknowledge that this list is 
incomplete and may include unapproved drugs 
from after 1962.13 The FDA believes that most 
Prescription Drug Wrap-up drugs first entered 
the market before 1938 in some form and had 
not been evaluated for safety or effectiveness. 
The FDA considers all drugs subject to the 
Prescription Drug Wrap-up to be marketed 
illegally, unless the manufacture of such a drug 
is grandfathered or not otherwise a new drug.13
Finally, some unapproved drugs were 
introduced to the market, or were changed, after 
enactment of the 1962 Amendments (ie, drugs 
not covered in the Prescription Drug Wrap-up). 
Other drugs were the subject of a formal new 
drug finding, defined as the introduction of 
a new delivery system of an approved drug. 
Examples include timed-release drugs and 
parenteral drugs in plastic containers. According 
to the FDA, drugs in this category are marketed 
illegally and are therefore subject to enforcement 
action unless covered by an NDA/ANDA.13
CURRENT FDA POSITION ON 
MARKETED, UNAPPROVED DRUGS
The FDA and the courts have interpreted the 
1938 and 1962 grandfather clauses in the FD&C 
Act in a limited fashion. The FDA contends that 
there are few, if any, drugs that are entitled to 
grandfathered status, because marketed drugs 
are likely to differ from the original versions 
in some respect (eg, formulation, dosage form, 
strength, manufacturing methods, route of 
administration, indications, and intended use 
in a specific patient population). Therefore, the 
FDA believes it is unlikely that any currently 
marketed drug is grandfathered or is otherwise 
not required to be FDA approved, but also 
recognizes that the existence of such drugs is 
theoretically possible. Over-the-counter (OTC) 
drugs were originally included in DESI, but the 
FDA eventually determined that it was not an 
effective use of resources to evaluate their status. 
As a result, the OTC Drug Review was instituted 
in 1972.13 The OTC Drug Review involved OTC 
rulemaking by therapeutic class (eg, antacids, 
cold remedies) using published monographs, 
setting forth permissible claims, labeling, and 
active ingredients for each therapeutic class. 
Monographs are defined as a statement that 
specifies the kinds and amounts of ingredients 
a drug, or class of drugs, may contain, the 
directions for use of the drug, the conditions in 
which it may be used, and the contraindications 
to its use. Drugs marketed in accordance with a 
final monograph are considered GRAS/E and do 
not require approval of a marketing application 
by the FDA. Unless the subject of an approved 
marketing application, OTC drugs are considered 
illegally marketed if approval is required because 
their ingredients or claims are not covered by 
the OTC Drug Review, or are not allowed as a 
result of a final monograph or another final 
rule.13 Figure 2 provides the FDA’s decision-
making tree for unapproved drugs.14
Because approximately 5,000 unapproved 
drug products continued to be marketed 
without required approval ,  the FDA 
implemented a risk-based enforcement 
program in June 2006 to focus its resources on 
products that pose the greatest threat to public 
health.1 The 2006 FDA initiative to remove 
unapproved drugs from the market included a 
final guidance entitled Marketed Unapproved 
Drugs - Compliance Policy Guide,1 which 
outlined enforcement policies designed to 
efficiently shepherd all such drugs through the 
approval process. This guidance was prepared 
by the FDA’s Center for Drug Evaluation and 
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administration to a 
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Figure 2. Decision tree for unapproved drugs.14 Although this decision tree provides an overall approach to understanding 
how marketed unapproved drugs may comply with requirements under the FDA’s current policies, as applied to any 
particular drug product, there may be variations and additional relevant factors. For instance, when a drug contains more 
than one active ingredient, each ingredient, as well as the combination as a whole, will need to be addressed. In addition, 
when an ingredient has been reviewed in more than one DESI proceeding, the agency will apply the regulation at 21 Code of 
Federal Regulation (CFR) 310.6 to determine which proceeding applies to a particular drug product. ANDA=Abbreviated 
New Drug Application; DESI=Drug Efficacy Study Implementation; NDA=New Drug Application; NOOH=Drug 
Efficacy Study Implementation Notice of Opportunity for Hearing; OTC=Over-the-Counter. 
UNAPPROVED DRUG DECISION TREE
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Research (CDER) and superseded previous 
policies on the marketing of new drugs 
without approved NDAs or ANDAs.1
The FDA can generally request voluntary 
compliance, post a notice of action in the Federal 
Register, present an untitled letter, issue a warning 
letter, and/or initiate a seizure, injunction, or 
proceeding to address the public health threat 
presented by an unapproved drug. However, 
these actions are time consuming and resource 
intensive.1 The intent of such guidance is to 
provide notice that an illegally marketed product 
is subject to FDA enforcement action at any 
time, which includes the provision of incentives 
for companies to obtain first-time approval 
for a previously unapproved drug, and allows 
for enforcement action against unapproved 
competitors of an approved product.1
The FDA advises that a warning letter may not 
be sent before enforcement action is initiated, 
and companies should not expect a grace period 
to protect them from leaving the market while 
obtaining approval.1 A grace period cannot be 
expected when public health requires a product 
to be immediately removed from the market 
or when specific prior notice has been given in 
the Federal Register, or otherwise, that a drug 
product requires approval from the FDA.1
EXAMPLES OF FDA ENFORCEMENT 
AGAINST UNAPPROVED DRUGS 
To date, there are several notable and well-
publicized actions of FDA enforcement that 
have been taken against drugs with a previous 
unapproved status.
Guaifenesin
In 2002, warning letters were sent by the FDA 
to 66 pharmaceutical manufacturers that were 
marketing unapproved, single-ingredient, 
extended-release guaifenesin products, 
claiming that the products were illegally 
marketed new drugs. This action was initiated 
after one manufacturer filed an NDA for its 
single-ingredient, extended-release product 
(Mucinex®; Reckitt Benckiser Inc, Berkshire, 
England), providing the FDA with the 
impetus for immediate enforcement. In 2007, 
the FDA required all competitors, after a grace 
period, to remove their products from the 
marketplace until an NDA was submitted.15
The FDA’s enforcement action on unapproved 
competitors of an approved product, in this 
case, incentivized companies to obtain legal 
approval for a previously unapproved drug.15
Carbinoxamine
In June 2006, after having received 21 reports 
of deaths in children younger than 2 years 
of age, the FDA ordered all manufacturers 
of unapproved products containing the 
antihistamine carbinoxamine, including 
carbinoxamine maleate and carbinoxamine 
tannate ,  to  d i scont inue  product ion, 
despite the inability to establish a causal 
relationship.16 Some of these carbinoxamine-
containing products, used for the treatment 
of cough and cold symptoms, had been 
promoted for use in infants and children 
younger than 2 years and in those as young 
as 1 month of age. The FDA has since 
determined that this drug is neither safe nor 
effective for this indication in this patient 
population. This action did not affect tablets 
or oral solutions where carbinoxamine was 
the only active ingredient (tablet and oral 
solution, respectively). The manufacturer 
had received prior FDA approval to market 
these products for the treatment of allergic 
reactions or such symptoms in patients older 
than 2 years.16
852 Adv Ther (2011)  28(10):842-856.
Levothyroxine
Levothyroxine was being used as therapy by 
more than 15 million Americans when the 
FDA determined that it was necessary to bring 
formulations of this drug into compliance 
with current regulations. Although its safety 
and efficacy had been established in published 
medical literature, the FDA had concerns about 
the quality of the formulations in relation to 
their stability and potency in consideration of 
potential manufacturing issues.13
In 1997, the FDA issued a notice declaring 
that all orally administered levothyroxine 
products should be classified as new drugs, 
thereby requiring manufacturers to obtain 
NDAs. However, the manufacturers were given 
an initial 3-year grace period by the FDA, which 
was later extended to 4 years to allow continued 
marketing. Manufacturers had initially claimed 
that levothyroxine was exempt from FDA 
approval, claiming that it was in the same class 
as natural thyroid drugs and should therefore 
be grandfathered. On this basis, manufacturers 
attempted to obtain GRAS/E status from the 
FDA. This claim was subsequently rejected by the 
FDA, and all marketed levothyroxine products, 
following NDA submissions, are considered 
approved drugs by the FDA.13
Nitroglycerin
The recent action by the FDA on unapproved 
sublingual nitroglycerin tablets offers another 
example of enforcement in practice. Only one 
nitroglycerin product (Nitrostat®; Pfizer Inc., 
New York, NY) has gained FDA approval, in 
2000, following NDA submission. However, 
other sublingual, unapproved nitroglycerin 
tablets have been available for prescription 
from manufacturers claiming GRAS/E status. 
In March 2010, the FDA issued warning letters 
to the manufacturers of these unapproved 
nitroglycerin tablets to cease manufacture 
and shipment of existing products.17 The FDA 
did not accept the GRAS/E status of these 
formulations and had not reviewed the quality 
or labeling of these products, and it was noted 
that there had been significant problems related 
to quality and efficacy with some unapproved 
nitroglycerin products.18
Colchicine
Perhaps the greatest case for FDA action 
and oversight in this regard can be made for 
unapproved colchicine, the “poster child” 
for the need for FDA approval. Extracts of 
the alkaloid colchicine have been used since 
antiquity for the treatment of patients with 
gout.19 A relatively pure, oral formulation of 
colchicine was isolated and prescribed from the 
late 19th century in the US and continued to 
be used, until recently, without having followed 
the formal FDA approval process for new drugs. 
Colchicine, therefore, escaped the obligatory, 
rigorous manufacturing standards and clinical 
studies to establish its efficacy and safety, as well 
as ancillary data for precise, reliable prescribing 
information, such as dosage recommendations, 
drug interactions, and use in special populations, 
that are required for new drugs by the FDA.19
Colchicine is metabolized to inactive 
metabolites by cytochrome P450 3A4 (CYP3A4)1 
and is a substrate for P-glycoprotein (P-gp),20
a key protein in the multi-drug resistance 
(MDR)-1 transport system. It is excreted by 
both renal and hepatic mechanisms involving 
MDR-1-mediated efflux of colchicine.21,22
Plasma colchicine concentrations can therefore 
be significantly increased by renal or hepatic 
insufficiency23 and/or by concomitant 
administration of CYP3A4 or P-gp inhibitors,24
situations that are more frequent in the 
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characteristically elderly population of patients 
with gout who are treated with colchicine. 
Furthermore, colchicine shows marked 
variability in disposition between individuals25
and its therapeutic index is narrow.25,26 High 
plasma colchicine concentrations cause 
characteristic diarrhea and, less frequently, 
serious and even fatal cases of myotoxicity and 
neurotoxicity.24-26
Colchicine is a prime example of an 
unapproved drug for which the FDA has 
enforced separate warnings for two different 
formulations. In February 2008, the FDA ordered 
all manufacturers of injectable colchicine, 
available since the 1950s as an unapproved 
drug in the US, to cease manufacturing and 
shipment and submit NDAs for continued 
marketing.19 This action was initiated by the 
FDA due to significant safety concerns, including 
167 deaths associated with the use of unapproved 
colchicine. The majority were at therapeutic 
doses, <2 g/day (n=117), of which half (n=60) 
were receiving clarithromycin concomitantly.27
There were 50 additional reports of serious 
adverse events (eg, neutropenia, acute renal 
failure, thrombocytopenia, congestive heart 
failure, and pancytopenia), 23 of which resulted 
in death.19 The FDA’s action did not affect oral 
formulations, which continued to be marketed 
as unapproved drugs.
In 2009, the FDA approved three NDAs for 
single-agent, oral colchicine (Colcrys®; Mutual 
Pharmaceutical Company, Inc., Philadelphia, 
PA), indicated for the treatment and prophylaxis 
of gout flares and familial Mediterranean 
fever.28 The FDA also took legal action against 
other companies that manufactured and/or 
distributed other, unapproved, oral formulations 
of colchicine based on false advertising and 
unfair competition theories. These unapproved 
oral formulations did not provide important 
safety data, instructions on drug interactions, 
or information on dosing that are provided 
in the prescribing information for the FDA-
approved oral formulation, Colcrys. For 
example, the prescribing information for 
Colcrys provides important dosing information 
in relation to potentially fatal drug interactions. 
Additionally, the dose of Colcrys for acute gout 
flares, as defined in its prescribing information 
(determined from a phase 3 clinical trial and 
included in its NDA), is lower than previously 
prescribed for unapproved, oral colchicine 
formulations, thereby reducing the risk of 
toxicity while retaining efficacy.29 Finally, because 
FDA manufacturing standards were applied, 
new processes were developed to remove toxic 
derivatives of colchicine from purification that 
had previously been unregulated. This resulted 
in a much purer form of active ingredient while 
reducing toxic ingredients below the 0.06% level 
required by the FDA.
Despite the overwhelming safety concerns 
associated with the use of unapproved colchicine 
that occurred before the FDA’s action to mandate 
the availability of single-source colchicine, 
controversy has been prominently raised. 
Primarily, this controversy arose in relation to 
increased acquisition costs for Colcrys without 
any proof of a meaningful improvement to 
public health.30 Yet, the true incidence of 
morbidity and mortality, and serious drug 
reactions associated with the use of unapproved 
colchicine, may be greatly underreported. From 
2007 to 2008, the estimated prevalence of 
gout was 8.3 million adults, or 3.9% of the US 
population.31 A considerable proportion of these 
patients received unapproved colchicine, thus 
indicating a significant target population.
Given the lack of  precise dosage 
recommendations, specific warnings for 
special populations (notably those with renal 
and/or hepatic insufficiency), and advice for 
dose adjustment during concomitant drug 
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administration (notably CYP3A4 or P-gp 
inhibitors) as required for FDA-approved 
medications, it is probable that a considerable 
proportion of patients with gout were exposed 
to toxicity with unapproved colchicine. 
Indeed, gastrointestinal manifestations 
have been reported to develop frequently 
(~91% of patients),26 which has limited the 
use of, and enthusiasm for, colchicine by 
patients.32 More overt and potentially fatal 
toxicity (myotoxicity and neurotoxicity, as 
well as bone marrow suppression) is associated 
with the higher colchicine exposure in patients 
receiving concomitant CYP3A4 or P-gp 
inhibitor administration, notably in those with 
intercurrent renal or hepatic insufficiency.26
Colcrys was approved for the treatment of 
acute gout attacks (as a single dose of 1.2 mg, 
followed by a dose of 0.6 mg 1 hour later) in 
adults. The registrational, randomized, double-
blind, parallel-group Acute Gout Flare Receiving 
Colchicine Evaluation (AGREE) trial compared 
the eventually approved, low-dose colchicine 
regimen of Colcrys (1.8 mg over 1 hour) with 
high-dose Colcrys (4.8 mg over 6 hours) and 
placebo in 184 patients with gout flare onset.31
Response rates (≥50% pain reduction at 24 hours 
without rescue medication) were 38%, 33%, and 
15% on low-dose Colcrys, high-dose Colcrys, and 
placebo, respectively.32 The incidence of adverse 
events was not significantly different between 
low-dose Colcrys and placebo (36% vs. 27%; odds 
ratio = 1.5 [95% CI, 0.7-3.2]), but was significantly 
higher (77%) in the high-dose Colcrys group. 
Therefore, the approved low-dose regimen 
resulted in an efficacy profile comparable to that 
of the high-dose regimen, but with a safety profile 
indistinguishable from placebo.16
Currently, the prescribing pattern of 
practitioners’ use of unapproved colchicine and 
Colcrys is not known, and it is also unknown 
whether or not the use of Colcrys has been 
definitively translated into improved patient 
safety. Investigations in this regard are ongoing.
CONCLUSION
The FDA defines legally marketed drugs as 
those that have an approved NDA (with generic 
versions of such drugs marketed under an 
approved ANDA) and those that are exempt 
from the FD&C Act. The latter group includes 
pre-1938 and pre-1962 grandfathered drugs, 
products subject to ongoing DESI proceedings, 
GRAS/E prescription drugs, and drugs that are 
marketed in accordance with a final, or tentative, 
OTC monograph. Unapproved illegally marketed 
drugs include drugs marketed outside an OTC 
drug final, or tentative final, monograph, those 
found to be ineffective under DESI but for 
which an NDA/ANDA has not been submitted, 
drugs subject to the Prescription Drug Wrap-up 
Program, new unapproved drugs, and drugs not 
meeting GRAS/E requirements or that differ 
from pre-1938 or pre-1962 grandfathered drugs. 
The FDA has estimated that several thousand 
unapproved drugs exist within these categories. 
The FDA currently gives priority status 
‘to enforcement action against unapproved 
drugs in the following categories: (1) drugs 
with potential safety risks; (2) drugs that lack 
evidence of effectiveness; (3) drugs that present 
a ‘health fraud’; (4) drugs that present direct 
challenges to the ‘new drug’ approval and OTC 
drug monograph systems; (5) unapproved ‘new 
drugs’ that are also violative of the FDC Act in 
other ways (eg, Current Good Manufacturing 
Practice [‘CGMP’] regulation violations); and 
(6) drugs that are reformulated to evade an 
FDA enforcement action (eg, when a firm, in 
anticipation of FDA enforcement action, changes 
its unapproved drug product by, for example, 
adding an active ingredient, in an attempt to 
evade such enforcement action).’13
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Finally, it is important to note that most of 
the unapproved drugs that have been targeted 
for enforcement by the FDA have lacked safety 
and/or efficacy data. A primary concern for the 
FDA remains the control of unapproved drugs in 
the market to ensure optimal public health and 
consumer protection.
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